SLC20A1 Antibody

What is SLC20A1 and why is it important to study?

SLC20A1, also known as PiT1, is a sodium-dependent phosphate symporter with a molecular weight of approximately 74 kDa (observed at ~85 kDa in some Western blots). It comprises 679 amino acid residues and is primarily localized in the cell membrane . SLC20A1 functions as a transporter that preferentially carries monovalent phosphate with a stoichiometry of two sodium ions per phosphate ion .

This protein plays several critical physiological roles:

• Fundamental housekeeping role in phosphate transport

• Absorption of phosphate from interstitial fluid

• Support of cellular metabolism, signal transduction, and nucleic acid/lipid synthesis

• Potential role in extracellular matrix and cartilage/vascular calcification

• Essential for cell proliferation independent of its phosphate transport activity

• Functions as a retroviral receptor for viruses like Gibbon Ape Leukemia Virus (GALV)

SLC20A1's ubiquitous expression across tissues and its involvement in fundamental cellular processes make it a significant research target.

What applications can SLC20A1 antibodies be used for?

SLC20A1 antibodies support multiple experimental applications:

Different antibodies show varying reactivity with species, with many recognizing human, mouse, and rat SLC20A1 . Always verify the specific antibody's reactivity for your species of interest.

How should I validate the specificity of an SLC20A1 antibody?

Proper validation of SLC20A1 antibodies is critical for experimental reliability:

• Knockout/Knockdown Controls:

  • Use CRISPR/Cas9-generated SLC20A1 knockout cells or siRNA knockdown

  • Compare with wild-type controls to confirm specificity

  • Example: Knockdown experiments described in research showed that "Knockdown of SLC20A1 confirmed the specificity of the SLC20A1 antibody that was used"

• Molecular Weight Verification:

  • Confirm observed molecular weight (typically 74-85 kDa)

  • Note any post-translational modifications that might affect migration

• Subcellular Localization:

  • Verify membrane localization by immunofluorescence

  • "Confocal imaging... revealed SLC20A1 localization predominantly at the plasma membrane"

• Cross-reactivity Testing:

  • Test on multiple cell lines and tissue types where SLC20A1 is known to be expressed

  • Use positive samples like "293T, A-431, HeLa, HT-1080, NCI-H460, Mouse liver, Mouse brain, Rat brain"

• Proper Controls:

  • Include isotype controls for monoclonal antibodies

  • Use pre-immune serum controls for polyclonal antibodies

What are the typical molecular weights observed for SLC20A1 in Western blot?

When detecting SLC20A1 using Western blot, researchers should be aware of potential variation in observed molecular weights:

• Theoretical molecular weight: 73.7-74 kDa

• Commonly observed molecular weight: ~85 kDa

This discrepancy may be attributed to:

• Post-translational modifications (glycosylation, phosphorylation)

• The transmembrane nature of the protein affecting migration

• Variations in gel running conditions or sample preparation

When interpreting results, note that literature reports show SLC20A1 is a complex transmembrane protein with 12 transmembrane helices and 7 extracellular regions , which may influence its migration pattern. Compare your observed molecular weight with positive controls and manufacturer specifications for your specific antibody.

How does phosphate starvation affect SLC20A1 detection and what methodological adjustments are needed?

Phosphate starvation significantly impacts SLC20A1 protein detection, requiring methodological considerations:

Effect on SLC20A1 Expression:

• Phosphate starvation induces striking SLC20A1 protein upregulation

• This phenomenon occurs across multiple cell lines (HEK293T, U-2 OS, HCT116, U-87 MG)

• Interestingly, mRNA levels show only mild increases despite strong protein induction

Methodological Adjustments:

• Time Course Experiments:

  • Include multiple time points (24h, 48h, 72h) of phosphate starvation

  • "Phosphate starvation for 48h" was sufficient to observe significant changes

• Antibody Dilution Optimization:

  • Re-optimize antibody dilutions as expression levels change dramatically

  • Consider using gradient dilutions to capture the full dynamic range

• Subcellular Fractionation:

  • Perform membrane fractionation to distinguish increased total protein from altered subcellular distribution

  • "Immunofluorescent staining... confirmed the immunoblot findings and revealed SLC20A1 localization predominantly at the plasma membrane"

• Flow Cytometry Quantification:

  • For high-throughput analysis, flow cytometry can be used to quantify SLC20A1 upregulation

  • "Flow cytometry confirmed that phosphate starvation increases cellular SLC20A1 levels"

• Control Experiments:

  • Include phosphate replete controls

  • Test cell-specific responses as they may vary by cell type

These adjustments enable accurate assessment of SLC20A1 regulation under phosphate-limited conditions.

What are the best practices for using SLC20A1 antibodies in cancer research, particularly for breast cancer subtypes?

SLC20A1 has emerged as a potential prognostic marker in breast cancer, requiring specific methodological approaches:

Research Context:

• SLC20A1high expression correlates with poor prognosis in ER+, claudin-low, and basal-like breast cancers

• SLC20A1high patients treated with radiotherapy showed poor clinical outcomes

• SLC20A1 knockdown suppresses viability in multiple breast cancer cell lines (MDA-MB 231, MDA-MB 468, MCF-7)

Methodological Best Practices:

• Subtype-Specific Analysis:

  • Stratify samples by molecular subtypes (PAM50 classification or IHC profiles)

  • Compare SLC20A1 expression across ER+, claudin-low, basal-like, and other subtypes

  • Document patient characteristics and treatment history alongside expression data

• Quantitative Expression Analysis:

  • Develop consistent thresholds for defining "SLC20A1high" vs. "SLC20A1low"

  • Use digital pathology tools for quantitative IHC scoring

  • Apply tissue microarrays for high-throughput screening across patient cohorts

• Clinical Correlation Methods:

  • Perform Kaplan-Meier survival analysis stratified by SLC20A1 expression

  • Adjust for confounding factors (age, stage, grade, treatment)

  • Correlate with treatment response metrics, particularly radiotherapy outcomes

• Functional Validation:

  • Complement antibody-based detection with siRNA knockdown experiments

  • Assess effects on cancer stem cell properties (e.g., using tumor-sphere formation assays with ALDH1high cells)

  • Evaluate both cancer cell viability and invasive/migratory capacity

• Technical Considerations:

  • Use antigen retrieval with TE buffer pH 9.0 for optimal IHC results

  • Include both normal breast tissue and known positive controls

  • Compare results across multiple antibody clones to ensure reproducibility

These approaches enable robust evaluation of SLC20A1 as both a prognostic marker and potential therapeutic target in breast cancer.

How can I use SLC20A1 antibodies in SCAM (Substituted Cysteine Accessibility Mutagenesis) for topology studies?

SCAM is a powerful method for defining membrane protein topology, as demonstrated in SLC20A1 research leading to a model with 12 transmembrane helices and 7 extracellular regions .

SCAM Methodology with SLC20A1 Antibodies:

• Site-Directed Mutagenesis Setup:

  • Generate a cysteine-less version of SLC20A1 by replacing all 13 native cysteines (positions 63, 132, 204, 238, 242, 251, 264, 403, 426, 468, 524, 573, 625) with alanines

  • Verify that cysteine-less SLC20A1 maintains function

  • Introduce single cysteines at positions of interest throughout the protein

• Epitope-Tagged Constructs:

  • Add C-terminal HA tags to SLC20A1 constructs for detection

  • "MDTF cells expressing mutant SLC20A1(PiT1) proteins containing C-terminal HA epitope tags were analyzed using flow cytometry"

• Antibody-Based Detection:

  • Use anti-HA antibodies for general detection (e.g., "anti-HA-Alexa Fluor 488 monoclonal antibody")

  • Apply anti-SLC20A1 antibodies for verification of expression and localization

  • Quantify antibody binding using standardized beads (e.g., "Quantum Simply Cellular anti-mouse IgG quantitative beads")

• Accessibility Analysis:

  • Treat intact cells with membrane-impermeable cysteine-reactive reagents

  • Fixed cells can be permeabilized to determine intracellular vs. extracellular accessibility

  • Compare labeling patterns across mutants to map topology

• Validation Steps:

  • Use known topology constraints to verify results

  • Combine with computational prediction methods (e.g., "HMMTOP, a hidden Markov model-based transmembrane topology prediction method")

  • Correlate accessibility data with functional assays

This approach minimally perturbs the structure and function of SLC20A1 while providing detailed topological information that has revised previous models of this important transporter.

What methods should be used to study interactions between SLC20A1 and ESCRT machinery proteins?

Recent research has revealed that the ESCRT (Endosomal Sorting Complex Required for Transport) machinery regulates SLC20A1 protein abundance . Here are methodological approaches to investigate this interaction:

• Co-Immunoprecipitation (Co-IP):

  • Use anti-SLC20A1 antibodies to pull down protein complexes

  • Probe for ESCRT components (VPS37A, CHMP6) in immunoprecipitates

  • Verify specificity using knockout controls: "sgVPS37A cells displayed increased abundance of SLC20A1 protein compared with sgControl cells"

• Reverse Co-IP:

  • Immunoprecipitate with antibodies against ESCRT components

  • Detect SLC20A1 in the precipitated complexes

  • Include appropriate controls (IgG, lysate input)

• Fluorescence Co-localization:

  • Express CHMP6-EGFP fusion protein which "leads to the accumulation of degradation-bound proteins"

  • Immunostain for SLC20A1 with Alexa 594-tagged secondary antibodies

  • Analyze using confocal microscopy: "Some cells contained intracellular SLC20A1 punctae and compartments. A subset of these compartments colocalized with CHMP6-EGFP"

• CRISPR/Cas9 Functional Studies:

  • Generate ESCRT component knockouts (e.g., VPS37A, CHMP6)

  • Quantify SLC20A1 protein levels by immunoblotting

  • Verify that changes occur post-transcriptionally by measuring mRNA levels

• Flow Cytometry Analysis:

  • Use fluorophore-conjugated anti-SLC20A1 antibodies

  • Quantify expression levels in wild-type vs. ESCRT-deficient cells

  • "Flow cytometry confirmed that... cellular SLC20A1 levels...can be surveyed in a high-throughput flow cytometry format"

These methods provide complementary approaches to characterize the functional relationship between SLC20A1 and the ESCRT machinery, revealing mechanisms of SLC20A1 regulation.

How can SLC20A1 antibodies be optimized for detecting post-translational modifications and protein variants?

Detecting SLC20A1 post-translational modifications (PTMs) and protein variants requires specialized approaches:

• Phosphorylation-Specific Detection:

  • Use phospho-specific antibodies targeting known SLC20A1 phosphorylation sites

  • Combine with phosphatase inhibitors during sample preparation

  • Validate with lambda phosphatase treatment as a negative control

  • Consider enrichment techniques like phosphopeptide immunoprecipitation before analysis

• Glycosylation Analysis:

  • Compare SLC20A1 migration patterns before and after deglycosylation (PNGase F treatment)

  • The difference between theoretical (74 kDa) and observed (85 kDa) molecular weights may reflect glycosylation

  • Use lectins alongside SLC20A1 antibodies for co-localization studies of glycosylated forms

• Isoform-Specific Detection:

  • Select antibodies targeting regions unique to specific SLC20A1 variants

  • Verify epitope locations relative to alternative splicing regions

  • For domains with high conservation across species (like PiT family regions), use antibodies raised against species-specific epitopes

• Sample Preparation Optimization:

  • For membrane proteins like SLC20A1 with "12 transmembrane helices and 7 extracellular regions" :

    • Use mild detergents (CHAPS, DDM) to preserve native conformation

    • Avoid excessive heating which can cause aggregation

    • Include protease and phosphatase inhibitor cocktails

• Validation Approaches:

  • Employ orthogonal methods (mass spectrometry) to confirm PTMs detected by antibodies

  • Use CRISPR/Cas9 to mutate specific modification sites and verify antibody specificity

  • Include cellular treatments known to alter PTM status (phosphatase inhibitors, glycosylation inhibitors)

These optimizations enable more precise characterization of SLC20A1 biology beyond simple protein detection.

What are the methodological considerations when using SLC20A1 antibodies in high-throughput genetic screening?

High-throughput genetic screening with SLC20A1 antibodies requires specific methodological considerations:

• Flow Cytometry-Based Screening:

  • Optimize antibody labeling for flow cytometry applications

  • Establish clear gating strategies for SLC20A1high vs. SLC20A1low populations

  • "Flow cytometry confirmed that... cellular SLC20A1 levels...can be surveyed in a high-throughput flow cytometry format that is suitable for large-scale genetic screening"

• CRISPR/Cas9 Screen Design:

  • Use whole-genome CRISPR/Cas9 libraries for unbiased screening

  • Example: "Whole-genome CRISPR/Cas9-based loss-of-function genetic screen in phosphate-replete HEK293T cells to identify genes whose absence leads to increased SLC20A1 protein levels"

  • Include non-targeting sgRNA controls and known regulators as benchmarks

• Antibody Selection Criteria:

  • Choose antibodies with minimal background in flow cytometry

  • Validate specificity in knockout cells before screening

  • Ensure consistent performance across batches for large-scale experiments

• Data Analysis Methods:

  • Apply bioinformatic approaches to identify significant hits

  • "Bioinformatic analyses of the genetic screening results revealed that cells expressing KO guide RNAs targeting ESCRT proteins contributed many of the candidates"

  • Cluster hits by functional categories or pathways

• Validation Pipeline:

  • Confirm top hits with individual knockouts/knockdowns

  • Verify protein changes by Western blot and qPCR to distinguish transcriptional from post-transcriptional effects

  • Example validation: "For validation of our genetic screening results, we created HEK293T cells deficient in the top-ranking proximal ESCRT I subunit VPS37A and the top-ranking distal ESCRT-III subunit CHMP6"

• Physiological Relevance Testing:

  • Examine effects under various conditions (phosphate starvation, cell stress)

  • Assess functional outcomes (phosphate transport, proliferation)

  • Extend findings to different cell types to establish generalizability

These methodological considerations enable robust high-throughput screening with SLC20A1 antibodies to identify novel regulatory mechanisms.